Liminatus Pharma, Inc. Class A Common Stock Total Liabilities
Liminatus Pharma, Inc. Class A Common Stock total liabilities. Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has total liabilities worth $3.10 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See LIMN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
Total liabilities of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025. This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
House of Doge Inc.
NASDAQ:HODO
|
USA | $23.87 Million |
|
Fairchild Gold Corp
V:FAIR
|
Canada | CA$504.25K |
|
Property Franchise Group PLC
LSE:TPFG
|
UK | GBX51.32 Million |
|
Gibb River Diamonds Limited
F:PHO
|
Germany | €363.93K |
|
Canasil Resources Inc.
V:CLZ
|
Canada | CA$465.15K |
|
PetroFrontier Corp
V:PFC
|
Canada | CA$24.14 Million |
|
Linkage Global Inc
NASDAQ:UZX
|
USA | $5.54 Million |
|
IMMO BLOCKCHAIN EO 1
F:QT5
|
Germany | €7.02 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Liminatus Pharma, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Liminatus Pharma, Inc. Class A Common St's balance sheet.
Liquidity & Leverage Metrics
Liminatus Pharma, Inc. Class A Common Stock Total Liabilities Ratios Explained
Liminatus Pharma, Inc. Class A Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 10.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liminatus Pharma, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the annual total liabilities of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.33 Million | -44.77% |
| 2024-12-31 | $18.70 Million | +23.06% |
| 2023-12-31 | $15.19 Million | +7.05% |
| 2022-12-31 | $14.19 Million | -34.20% |
| 2021-12-31 | $21.57 Million | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.